Torrent Pharmaceuticals reported a strong performance for the fourth quarter ended March 31, 2026, with revenues reaching ₹4,197 crore, reflecting a 42% year-over-year growth. The company also announced a final dividend of ₹9 per equity share and unveiled plans to raise up to ₹5,000 crore through qualified institutional placements. The successful integration of JB Pharma has been a key driver in these results, significantly bolstering the company’s market position.
Financial Performance Highlights
For the quarter ended March 31, 2026, Torrent Pharmaceuticals demonstrated significant growth. Reported revenue stood at ₹4,197 crore, a 42% increase compared to the same period last year. The operating EBITDA was recorded at ₹1,356 crore, up by 41%, with an operating EBITDA margin of 32.3%. For the full FY26, the company achieved total revenues of ₹13,980 crore, representing a 21% year-over-year increase.
Strategic Growth and Acquisition
The company successfully integrated the newly acquired JB Pharma, which has significantly contributed to its consolidated financials. Following the acquisition of a controlling stake, Torrent Pharma is now focused on operational synergies and restructuring its distribution network. To fuel future expansion and strategic initiatives, the board has recommended enabling shareholders’ approval to raise up to ₹5,000 crore through the issuance of equity shares, convertible bonds, or debentures via Qualified Institutional Placement (QIP).
Dividend Announcement
Recognizing the company’s strong financial health and value creation for its stakeholders, the Board has recommended a final dividend of ₹9 per equity share (180% on a face value of ₹5 each). If approved by shareholders at the upcoming Annual General Meeting, this dividend is proposed to be paid on or around June 25, 2026. The company has set May 29, 2026, as the record date for determining the eligibility of shareholders for this payout.
Market Performance
The base business continues to show resilience. Excluding the impact of the JB Pharma acquisition, the base business recorded a revenue growth of 16% for the quarter and 15% for the full fiscal year. The company saw strong performance across key geographies, with India business revenues growing by 43%, Brazil by 30%, and the United States business by 31%, underscoring the success of its focused specialty business strategy.
Source: BSE
